DEFR14A: Masimo Faces Proxy Contest Amidst Strategic Separation Plans

Masimo is engaged in a proxy contest while evaluating the separation of its consumer business to unlock stockholder value.

Summary

• Masimo Corporation is facing a proxy contest that management believes threatens its innovation and success.
• The company is considering separating its consumer products into a new company to foster growth and benefit stakeholders.
• In 2023, Masimo achieved successes including FDA clearances for Oxygen Reserve Index (ORi) and the Masimo SET-based Opioid Halo.
• The company also saw record-breaking numbers in incremental sales, hospital contract wins, and customer renewals.
• Hearables and wearables revenue grew by 93%, brain monitoring by 19%, and rainbow and hemodynamics by 16%.
• The Board of Directors began evaluating a proposed separation of the company's consumer business to unlock value for stockholders.
• The Board is implementing a phased-in declassification, becoming fully declassified by the 2026 Annual Meeting.
• Executive compensation programs were adjusted to further align with stockholder interests, including three-year cumulative performance periods for equity-based incentive awards.
• No annual cash bonuses were paid to executive officers for 2023 due to unmet performance targets.
• A group led by Politan Capital Management is seeking to nominate two directors, potentially gaining majority control of the Board despite holding less than 9% of outstanding shares.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While highlighting innovation and growth in certain areas, it also acknowledges challenges, a proxy contest, and unmet financial targets. The proxy contest and potential change in control introduce uncertainty.

Positives

• Masimo achieved FDA clearances for innovative products like Oxygen Reserve Index (ORi) and the Masimo SET-based Opioid Halo.
• The company experienced record-breaking numbers in incremental sales, hospital contract wins, and customer renewals.
• Significant revenue growth was seen in hearables and wearables (93%), brain monitoring (19%), and rainbow and hemodynamics (16%).
• The Board is responding to stockholder feedback by evaluating a separation of the consumer business and enhancing corporate governance.
• Executive compensation programs are being adjusted to better align with stockholder interests and long-term performance.

Negatives

• Masimo is currently facing a proxy contest, which management views as a threat to the company's innovation and success.
• No annual cash bonuses were paid to executive officers for 2023 due to unmet performance targets.
• A group led by Politan Capital Management is seeking to nominate two directors, potentially gaining majority control of the Board despite holding less than 9% of outstanding shares.

Risks

• The proxy contest could disrupt Masimo's culture of innovation and potentially lead to a loss of key talent.
• An ill-conceived change of control could jeopardize the company's long-term growth and potential.
• The Politan Group gaining majority control of the Board with a minority shareholding poses a risk to the company's strategic direction.

Future Outlook

Masimo remains focused on delivering technologies that transform care delivery and better connect the care ecosystem, as well as disruptive innovations that change the way consumers look after themselves, with plans to announce new product innovations in the coming months.

Management Comments

• Joe Kiani: 'Masimo has a great history of solving the unsolvable, and I am confident we are well positioned to continue bringing life-changing products to market.'
• Craig Reynolds: 'The Board is focused on fostering a culture of innovation, accountability and commitment to our goal of creating long-term value for stockholders and our mission of improving lives.'

Industry Context

The announcement highlights Masimo's efforts to innovate in patient monitoring and consumer health, aligning with broader trends in healthcare technology and remote patient management. Competitors in patient monitoring include Medtronic, Philips, and GE Healthcare. In the consumer audio space, Masimo competes with companies like Apple, Bose, and Sony.

Comparison to Industry Standards

• Masimo's growth in hearables and wearables (+93%) significantly outpaces the average growth in the consumer electronics sector, which is estimated to be around 5-10% annually.
• The company's focus on FDA clearances for its products, such as the Opioid Halo, aligns with the industry's increasing emphasis on regulatory compliance and patient safety, similar to companies like Dexcom and Insulet.
• The potential separation of the consumer business mirrors strategies employed by companies like Philips, which have divested certain business units to focus on core healthcare operations.

Corporate Governance

Legal Proceedings

• The Company commenced litigation against Politan, including Mr. Koffey and Ms. Brennan, in the United States District Court for the Central District of California (the Section 14(a) Action) seeking, among other things, an order declaring that Politans proxy materials for the 2024 Annual Meeting violate Section 14(a) of the Securities Exchange Act of 1934, as amended, an order enjoining Politan from voting any proxies received by means of Politans misleading proxy material, an order invalidating any proxies Politan or other persons acting in concert with it obtained pursuant to the misleading proxy material and an injunction requiring Politan to correct material misstatements and omissions in Politans proxy materials for the 2024 Annual Meeting.
• On July 17, 2024, despite Politans multiple requests that the Company move the record date for the 2024 Annual Meeting, Politan commenced litigation against the Company in the Court of Chancery of the State of Delaware alleging that Messrs. Kiani, Reynolds and Chapek breached their fiduciary duties to the Company by moving the date of the 2024 Annual Meeting.

Related Party Transactions

• The company has a cross-licensing agreement with Willow Laboratories, Inc., where Joe Kiani is also the Chairman and CEO, resulting in royalty payment liabilities of approximately $19.2 million for fiscal 2023.
• The company has a services agreement with Willow Laboratories, Inc., resulting in payments to Masimo of approximately $0.5 million for general and administrative services rendered in fiscal 2023.
• The company leases space from Willow Laboratories, Inc., resulting in lease income of approximately $1.2 million during fiscal 2023.
• The company made approximately $1.0 million in cash contributions to the Masimo Foundation for Ethics, Innovation and Competition in Healthcare, where Joe Kiani is also the Chairman.
• The company incurred $1.5 million in marketing expenses payable to Like Minded Media Ventures, where Joe Kiani is also a member of the Board of Directors, under a marketing service agreement.

Stakeholder Impact

• Shareholders face uncertainty due to the proxy contest and potential changes in board control.
• Employees may experience changes in the company's culture and strategic direction depending on the outcome of the proxy contest.
• Customers could see shifts in product development and service offerings based on the company's future strategic direction.
• Suppliers and creditors may be affected by changes in the company's financial performance and strategic priorities.

Next Steps

• Stockholders are urged to vote using the GOLD proxy card.
• The Board will continue to evaluate proposed structures for the separation of the consumer business and provide updates as appropriate.
• The Company will announce new product innovations in the coming months that it believes will transform patient monitoring.

Key Dates

Keywords

proxy contest, Masimo, corporate governance, executive compensation, Politan Capital Management, board of directors, stockholder value, annual meeting, director nominees, consumer business separation